Sara Berrade-Zubiri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sara Berrade-Zubiri has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Antonio García-Hermoso
Navarrabiomed, Hospital Universitario de Navarra, Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain
1 shared publication - Ignacio Hormazábal-Aguayo
Navarrabiomed, Hospital Universitario de Navarra, Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain
1 shared publication - Jacinto Muñoz-Pardeza
Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain
1 shared publication - José Francisco López-Gil
School of Medicine, Universidad Espíritu Santo, Samborondón 092301, Ecuador
1 shared publication - Maria J. Chueca‐Guindulain
Pediatric Endocrinology Unit, Hospital Universitario de Navarra, Instituto de Investigación Sanitaria de Navarra 3 , Pamplona, Spain
1 shared publication - Nidia Huerta-Uribe
Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Instituto de Investigación Sanitaria de Navarra 1 , Pamplona, Spain
1 shared publication
Latest Publications
- 13 August 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (10) , 1803-1811
Effect of Diactive-1 mHealth-Supported Progressive Resistance Training on Insulin Requirements, Glycemic Stability, and Muscular Strength in Children and Adolescents With Type 1 Diabetes: A Parallel-Group Randomized Controlled Trial
OBJECTIVE: To evaluate the effects of resistance training supported by the mobile health application Diactive-1 on the daily insulin dose and glycemic parameters in children and adolescents with type 1 diabetes. RESEARCH DESIGN AND METHODS: In this 24-week randomized clinical trial, Diactive-1 generated progressive overload resistance training sessions tailored to real-time glycemia and provided educational support. Insulin and glycemic parameters were collected from LibreView or CareLink, whereas glycosylated hemoglobin (HbA1c) was extracted from medical records. Muscular strength was assessed using a handgrip dynamometer and e-GYM machines, targeting pushing, pulling, and lower-limb movements. The effect was analyzed using linear mixed models. RESULTS: Sixty-two participants (age: 8–18 years, girls: 48%) with type 1 diabetes (HbA1c: 7.6% [60.4 mmol/mol]) were allocated to the usual care (n = 32) or the Diactive-1 group (n = 30). Daily insulin dose reductions were observed within the Diactive-1 group (mean difference [MD] −0.10 units/kg, 95% CI −0.18 to −0.01) and when compared with usual care (MD −0.17 units/kg, 95% CI −0.26 to −0.07). No adverse effects were observed on the glycemic risk index or the incidence of hypoglycemic events. Finally, handgrip strength (MD 2.90 kg, 95% CI 1.57–4.22), one-repetition maximum strength (MD 1.34, 95% CI 0.21–2.46), and muscular power (MD 0.97, 95% CI 0.01–1.93) increased. Four participants (6.5%) withdrew from the study. CONCLUSIONS: Diactive-1 appears to be a safe and feasible adjunct to standard care in children and adolescents with type 1 diabetes. Its resistance training component effectively reduced insulin requirements and improved muscular strength, without increasing the risk of adverse glycemic events.
- 13 August 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (10) , 1803-1811
Effect of Diactive-1 mHealth-Supported Progressive Resistance Training on Insulin Requirements, Glycemic Stability, and Muscular Strength in Children and Adolescents With Type 1 Diabetes: A Parallel-Group Randomized Controlled Trial
OBJECTIVE: To evaluate the effects of resistance training supported by the mobile health application Diactive-1 on the daily insulin dose and glycemic parameters in children and adolescents with type 1 diabetes. RESEARCH DESIGN AND METHODS: In this 24-week randomized clinical trial, Diactive-1 generated progressive overload resistance training sessions tailored to real-time glycemia and provided educational support. Insulin and glycemic parameters were collected from LibreView or CareLink, whereas glycosylated hemoglobin (HbA1c) was extracted from medical records. Muscular strength was assessed using a handgrip dynamometer and e-GYM machines, targeting pushing, pulling, and lower-limb movements. The effect was analyzed using linear mixed models. RESULTS: Sixty-two participants (age: 8–18 years, girls: 48%) with type 1 diabetes (HbA1c: 7.6% [60.4 mmol/mol]) were allocated to the usual care (n = 32) or the Diactive-1 group (n = 30). Daily insulin dose reductions were observed within the Diactive-1 group (mean difference [MD] −0.10 units/kg, 95% CI −0.18 to −0.01) and when compared with usual care (MD −0.17 units/kg, 95% CI −0.26 to −0.07). No adverse effects were observed on the glycemic risk index or the incidence of hypoglycemic events. Finally, handgrip strength (MD 2.90 kg, 95% CI 1.57–4.22), one-repetition maximum strength (MD 1.34, 95% CI 0.21–2.46), and muscular power (MD 0.97, 95% CI 0.01–1.93) increased. Four participants (6.5%) withdrew from the study. CONCLUSIONS: Diactive-1 appears to be a safe and feasible adjunct to standard care in children and adolescents with type 1 diabetes. Its resistance training component effectively reduced insulin requirements and improved muscular strength, without increasing the risk of adverse glycemic events.